Fetal Echocardiography in India
Get Fetal Echocardiography at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Fetal Echocardiography in UAE
Fetal Echocardiography at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Fetal echocardiography is a specialized prenatal ultrasound examination that uses high-frequency sound waves to produce detailed real-time images of the fetal heart, enabling clinicians to detect structural congenital heart defects (CHDs), arrhythmias, and hemodynamic abnormalities as early as 18–24 weeks of gestation with a diagnostic accuracy exceeding 85–92% for major cardiac anomalies. India and the UAE have emerged as premier destinations for this procedure, offering internationally accredited fetal cardiology units equipped with advanced 4D spatio-temporal image correlation (STIC) technology, expert pediatric cardiologists, and significantly lower costs compared to Western healthcare systems. GAF Healthcare connects international patients with rigorously vetted, JCI- and NABH-accredited centers in India and JCI- and DHA-licensed facilities in Dubai and Abu Dhabi, providing end-to-end care coordination from the initial scan through to post-diagnostic counseling and, where required, onward referral for fetal or neonatal cardiac intervention.
Hospital Stay: 0 days (outpatient procedure; no hospitalization required for diagnostic echocardiography alone) • Total Stay in Country (Fit-to-Fly): Same day to 2 days (the scan itself involves no sedation or invasive intervention for the mother; international travel is typically safe within 24–48 hours, subject to the treating obstetrician's clearance and gestational age considerations for air travel) • Success Rate: 85–92% diagnostic sensitivity for major structural congenital heart defects; up to 97–99% for critical lesions such as hypoplastic left heart syndrome, transposition of the great arteries, and tetralogy of Fallot when performed at tertiary fetal cardiology centers
What Is It?
Congenital heart disease (CHD) is the most common structural birth defect, affecting approximately 8 per 1,000 live births globally, and accounts for the largest share of infant mortality attributable to congenital anomalies. The fetal heart completes its primary structural development between weeks 3 and 8 of gestation; however, subtle defects in septal formation, valve morphology, outflow tract alignment, and great vessel anatomy may only become sonographically appreciable between 18 and 28 weeks. Fetal echocardiography goes far beyond the standard four-chamber cardiac view obtained during routine anomaly scans: it systematically evaluates all four cardiac chambers, the atrioventricular and semilunar valves, the ventricular outflow tracts, the great vessels (aorta and pulmonary artery), the ductus arteriosus, venous connections (superior and inferior vena cava, pulmonary veins), and cardiac rhythm. This comprehensive segmental approach allows for precise anatomical diagnosis of lesions ranging from small ventricular septal defects (VSDs) and atrioventricular septal defects (AVSDs) to complex conotruncal malformations and hypoplastic ventricles.
The physiological impact of an undetected or late-detected CHD can be catastrophic. Neonates born with critical CHD — defined as defects requiring surgery or catheter-based intervention within the first year of life — may present with ductal-dependent circulation and cardiovascular collapse within hours of birth if prostaglandin therapy is not initiated promptly. Prenatal diagnosis allows the obstetric and neonatal team to plan delivery at a cardiac center, secure intravenous access and prostaglandin E1 infusion at birth, and schedule corrective surgery in an elective rather than emergency setting, which significantly improves surgical outcomes and reduces perioperative mortality. Fetal echocardiography also plays a pivotal role in diagnosing fetal arrhythmias — including supraventricular tachycardia (SVT), complete heart block (often associated with maternal anti-Ro/La antibodies in connective tissue disease), and atrial flutter — enabling in-utero pharmacological therapy with digoxin, flecainide, or sotalol administered transplacentally to the mother.
The standard of care at leading centers in India and the UAE employs a multimodal echocardiographic protocol: two-dimensional (2D) B-mode imaging for structural assessment, M-mode for cardiac dimensions and ventricular function, pulsed-wave and continuous-wave Doppler for flow velocity and pressure gradient estimation, color flow Doppler mapping for detecting shunts and regurgitation, and — increasingly — four-dimensional echocardiography with spatio-temporal image correlation (4D-STIC). The STIC technique acquires a volume dataset of the fetal heart across a single cardiac cycle, which can then be reconstructed and navigated offline in any plane, dramatically improving diagnostic yield for outflow tract anomalies and vascular abnormalities that are notoriously difficult to image in real time. Tissue Doppler imaging (TDI) and myocardial performance index (MPI / Tei index) provide additional quantitative data on global and segmental myocardial function, particularly useful in monitoring fetuses with growth restriction, twin-to-twin transfusion syndrome (TTTS), or those exposed to maternal diabetes or teratogenic agents.
Candidates
• INDICATIONS — WHO SHOULD UNDERGO FETAL ECHOCARDIOGRAPHY:
• Fetuses with an abnormal or suboptimal cardiac view on routine anatomy scan (standard indication at any center)
• Family history of congenital heart disease: CHD in a first-degree relative (risk rises from 0.8% in general population to 3–5% with one affected sibling, and up to 10–15% with an affected parent)
• Prior sibling or child born with CHD (recurrence risk varies by lesion type: up to 14% for atrioventricular septal defect)
• Maternal diabetes mellitus (pre-gestational; risk of CHD approximately 3–5 times higher than background population, particularly for ventricular septal defects and transposition of the great arteries)
• Maternal autoimmune disease with anti-Ro/SSA or anti-La/SSB antibodies (associated with fetal complete heart block; serial echocardiography recommended from 16–28 weeks)
• Maternal phenylketonuria (PKU) with elevated phenylalanine levels during pregnancy
• Maternal rubella infection or other TORCH infections in first trimester
• Maternal use of teratogenic medications during cardiac organogenesis: lithium (Ebstein anomaly), retinoic acid, antiepileptic drugs (valproate, carbamazepine), NSAIDs in third trimester (premature ductus closure)
• Fetal chromosomal abnormalities or suspected aneuploidy: Trisomy 21 (Down syndrome) — 40–50% CHD rate; Trisomy 18 — 90%+ CHD rate; Trisomy 13; Turner syndrome (45,X) — bicuspid aortic valve, coarctation of the aorta; 22q11.2 deletion (DiGeorge syndrome) — conotruncal defects
• Increased fetal nuchal translucency (NT ≥3.5 mm) even with normal karyotype
• Non-immune fetal hydrops (cardiac cause must be excluded)
• Fetal extracardiac structural anomaly detected on anatomy scan
• Suspected or confirmed fetal arrhythmia on obstetric monitoring (irregular or abnormal heart rate)
• Monochorionic twin pregnancy (risk of TTTS with secondary cardiac dysfunction)
• In-vitro fertilization (IVF) or assisted reproductive technology (ART) conception (modestly elevated CHD risk)
• Fetal growth restriction (FGR) with abnormal Doppler indices suggesting cardiac compromise
• REQUIRED PRIOR INVESTIGATIONS AND INFORMATION:
• Complete first- and second-trimester ultrasound reports including NT measurement, anatomy scan findings, and Doppler studies
• Maternal medical history: diabetes control (HbA1c), autoimmune workup (ANA, anti-Ro/La antibodies), medication list
• Karyotype or chromosomal microarray results if available (NIPT, amniocentesis, or CVS)
• Maternal blood group and Rh status
• Gestational age confirmation (last menstrual period and crown-rump length dating)
• OPTIMAL GESTATIONAL TIMING FOR THE SCAN:
• Primary fetal echocardiography: 18–24 weeks (optimal cardiac visualization; most structures well-defined)
• Early fetal echo (first-trimester): 13–16 weeks using transvaginal probe in selected high-risk cases (sensitivity lower; incomplete for some structures)
• Repeat or follow-up scan: as indicated clinically (e.g., every 1–2 weeks in arrhythmia monitoring; at 28–32 weeks for cardiac function in TTTS post-laser)
• RELATIVE CONTRAINDICATIONS AND LIMITING FACTORS:
• Maternal obesity (BMI >35): may significantly limit acoustic windows; transvaginal approach or 4D-STIC may partially compensate
• Unfavorable fetal lie (posterior spine position) or excessive fetal movement: scan may need to be rescheduled
• Oligohydramnios: reduced fluid volume limits ultrasound transmission and cardiac visualization
• Gestational age <16 weeks (for transabdominal approach): cardiac structures too small for full segmental analysis in most cases
• No absolute medical contraindication to diagnostic ultrasound exists (non-ionizing, non-invasive for mother and fetus)
Procedure
Fetal echocardiography is a diagnostic — not interventional — procedure for the mother; however, it informs a spectrum of management strategies ranging from watchful surveillance to complex fetal or neonatal cardiac intervention. Understanding the full suite of diagnostic modalities and downstream treatment pathways is essential for international patients planning their care journey.
**1. STANDARD 2D/M-MODE FETAL ECHOCARDIOGRAPHY (BASELINE PROTOCOL)**
The foundational examination employs a systematic segmental approach: (a) determination of fetal situs and cardiac position (dextrocardia, levocardia, mesocardia); (b) four-chamber view with assessment of chamber symmetry, septal integrity, and atrioventricular valve morphology; (c) left and right ventricular outflow tract views (LVOT, RVOT); (d) three-vessel view and three-vessel-trachea view (3VT) for great vessel size, alignment, and ductal arch; (e) aortic and ductal arch views in sagittal plane; (f) venous connections including pulmonary veins. M-mode is used for cardiac biometry (ventricular dimensions, wall thickness) and arrhythmia characterization (simultaneous AV mechanical activity). This protocol takes approximately 45–75 minutes in a routine case and longer in complex anatomy.
**2. COLOR FLOW DOPPLER MAPPING**
Color Doppler is superimposed on the 2D image to visualize direction and turbulence of blood flow. It is indispensable for detecting ventricular septal defects (VSDs), atrial septal defects (ASDs), patent foramen ovale (PFO) patency assessment, valvular regurgitation, and outflow tract obstruction. Aliasing patterns guide placement of spectral Doppler gates for quantitative velocity measurement.
**3. PULSED-WAVE AND CONTINUOUS-WAVE SPECTRAL DOPPLER**
Pulsed-wave (PW) Doppler measures flow velocities at specific anatomical locations: mitral and tricuspid inflow (E/A ratio for diastolic function assessment), aortic and pulmonary valve peak velocities, ductus venosus waveform (correlating with right heart filling pressures), umbilical artery and middle cerebral artery Doppler for fetal wellbeing context. Continuous-wave (CW) Doppler is used where peak velocities exceed the PW Nyquist limit, such as in aortic or pulmonary stenosis. The pulmonary valve Doppler peak velocity and acceleration time-to-ejection time ratio (AT/ET) can estimate fetal pulmonary arterial pressure, aiding in the diagnosis of pulmonary hypertension or coarctation of the aorta.
**4. 4D ECHOCARDIOGRAPHY WITH SPATIO-TEMPORAL IMAGE CORRELATION (STIC)**
Spatiotemporal image correlation (STIC) is the most significant recent technological advance in fetal cardiac imaging. The transducer acquires a volume sweep of the fetal heart over 7.5–15 seconds, gating frames to the cardiac cycle based on continuous B-mode flicker detection. The reconstructed 4D volume allows offline navigation in any tomographic plane — including the outflow tract views that are most challenging to obtain in real time. STIC can be combined with color Doppler (color STIC) or B-flow imaging for enhanced vascular visualization. Studies demonstrate that STIC improves the detection rate of conotruncal anomalies (tetralogy of Fallot, double outlet right ventricle, truncus arteriosus, transposition of the great arteries) by 15–25% compared to 2D alone. STIC datasets can be transmitted electronically for remote expert review — a capability that is routinely utilized in GAF Healthcare's telecardiology network.
**5. TISSUE DOPPLER IMAGING (TDI) AND MYOCARDIAL PERFORMANCE INDEX (MPI)**
Tissue Doppler imaging measures myocardial wall velocities rather than blood flow velocities, providing quantitative assessment of systolic (S') and diastolic (E', A') myocardial function at the level of the mitral and tricuspid annuli. The myocardial performance index (Tei index) — calculated as (isovolumetric contraction time + isovolumetric relaxation time) / ejection time — is a load-independent global measure of both systolic and diastolic ventricular function. TDI and MPI are particularly valuable in fetuses with cardiomyopathy, TTTS cardiac compromise, diabetic embryopathy, or exposure to indomethacin (which causes ductus constriction and elevated right heart pressures).
**6. B-FLOW IMAGING AND HIGH-DEFINITION COLOR FLOW (HD-FLOW)**
B-Flow is a non-Doppler angle-independent technique that directly displays blood echogenicity using coded excitation, producing high-resolution images of flow within small cardiac structures without the color bleeding artifact that can obscure fine anatomical detail. It is particularly useful for delineating pulmonary venous connections, coronary artery origins, and small septal defects.
**7. FETAL MAGNETOCARDIOGRAPHY (fMCG) — AVAILABLE AT SELECTED CENTERS**
At a small number of advanced centers in India (including some IIT-affiliated research hospitals), fetal magnetocardiography using superconducting quantum interference device (SQUID) technology can non-invasively record the fetal cardiac magnetic field, providing electrophysiological data analogous to an ECG. This is the gold standard for characterizing complex fetal arrhythmias (particularly in distinguishing second- from third-degree heart block and in identifying accessory pathways in SVT) when M-mode and Doppler are insufficient.
**8. DOWNSTREAM INTERVENTION OPTIONS (INFORMED BY THE ECHO FINDINGS)**
The echocardiographic diagnosis directly determines the management pathway:
• **Conservative surveillance**: For hemodynamically insignificant defects (small perimembranous VSD, PFO, trivial valvular regurgitation) — serial echocardiography and planned delivery at a unit with neonatal cardiac backup.
• **In-utero pharmacological therapy**: For fetal SVT or atrial flutter, transplacental digoxin, flecainide, or amiodarone; for complete heart block, maternal dexamethasone (controversial, used in incomplete block to prevent progression). For premature ductus constriction, cessation of causal medication.
• **Fetal cardiac intervention (FCI)**: Available at a small number of highly specialized centers in India (e.g., Narayana Health, Amrita Institute) and UAE (Cleveland Clinic Abu Dhabi). FCI involves ultrasound-guided needle passage through the maternal abdomen, uterus, and fetal chest wall to access the fetal heart:
- *Fetal aortic valvuloplasty*: For evolving hypoplastic left heart syndrome (HLHS) secondary to severe aortic stenosis with left ventricular dysfunction; balloon dilation of the aortic valve at 22–28 weeks may preserve left ventricular growth and enable biventricular repair at birth.
- *Fetal pulmonary valvuloplasty*: For pulmonary atresia with intact ventricular septum and right ventricular growth potential.
- *Balloon atrial septostomy (BAS) in utero*: For highly restrictive or intact atrial septum in HLHS, to decompress the pulmonary circulation prior to birth.
• **Planned neonatal intervention**: The majority of prenatally diagnosed CHD is managed with postnatal surgery or catheter intervention; prenatal echo allows optimal site-of-delivery planning, PROSTIN (PGE1) availability at birth, and early surgical scheduling.
Cost of Fetal Echocardiography: India vs. UAE
Fetal echocardiography performed at internationally accredited centers in India and the UAE offers a substantial cost advantage over equivalent studies in the United Kingdom, United States, Canada, or Australia, without compromise in technological capability or physician expertise. The cost differential is primarily driven by lower operational overhead, equipment amortization, and physician fee structures rather than any reduction in the quality of the imaging protocol or reporting. Both destinations offer 4D-STIC-capable ultrasound platforms (GE Voluson E10/E8, Philips EPIQ, Samsung WS80A), internationally trained fetal cardiologists (many with fellowship training from UK, USA, or European centres), and English-language reporting. India offers the greatest cost savings — typically 60–75% below Western rates — while the UAE provides a premium, internationally connected experience with comparably lower cost than Western Europe and North America.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $150 – $500 | ~59% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $400 – $1,200 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
**PHASE 1: PRE-ARRIVAL PREPARATION (2–4 weeks before travel)**
• Step 1 — GAF Healthcare Initial Consultation: Submit all prior ultrasound reports, maternal history, and genetic reports through the GAF Healthcare patient portal. A dedicated case coordinator assigns a fetal cardiologist and confirms appointment availability. GAF Healthcare's medical team reviews the referral and advises on the optimal gestational window for travel.
• Step 2 — Document and Visa Preparation: For India, GAF Healthcare assists with the e-Medical Visa application (typically processed in 3–5 business days; patient must provide passport, photograph, hospital invitation letter, and proof of sufficient funds). For UAE, many nationalities receive visa-on-arrival or 30-day tourist/medical visas; GAF Healthcare provides the UAE facility's medical invitation letter where required.
• Step 3 — Pre-Travel Health Check: Patient's local obstetrician confirms fitness for air travel at the relevant gestational age (RCOG/ACOG guidelines generally permit air travel up to 36 weeks for uncomplicated singleton pregnancies; airlines may require a physician's letter beyond 28–32 weeks). Blood group, complete blood count, and any relevant serology are performed locally and results forwarded to GAF Healthcare.
• Step 4 — Logistics Coordination: GAF Healthcare arranges airport transfer (wheelchair-accessible vehicle if required), hotel accommodation for patient and attendant within 5–10 minutes of the hospital, and a dedicated multilingual patient coordinator who will be present throughout.
**PHASE 2: ARRIVAL AND PREPARATION (Day 1)**
• Step 5 — Arrival and Welcome: Airport pickup by GAF Healthcare representative with name-sign and patient file. Transfer to hospital for administrative registration and insurance documentation (if applicable). Check-in to hospital-adjacent accommodation.
• Step 6 — Pre-Scan Clinical Assessment: The fetal cardiologist conducts a detailed intake consultation reviewing all prior records, maternal history, and indication for the scan. A brief maternal physical assessment is performed. The cardiologist explains the scan protocol, the imaging views to be acquired, and the likely differential diagnoses, ensuring the patient provides informed consent.
• Step 7 — Pre-Scan Positioning Optimization: Patient is advised to have a light meal approximately 1–2 hours before the scan (a mildly active fetus with good amniotic fluid facilitates cardiac visualization). Bladder preparation is not required for transabdominal scans at mid-trimester.
**PHASE 3: THE FETAL ECHOCARDIOGRAPHY PROCEDURE (Day 1–2, Outpatient)**
• Step 8 — The Scan (45–90 minutes, occasionally longer in complex cases): The patient lies in a semi-reclined or left lateral tilt position. Ultrasound gel is applied to the abdomen. The sonographer or fetal cardiologist systematically acquires all required imaging planes using 2D, M-mode, pulsed and continuous-wave Doppler, color flow Doppler, and 4D-STIC as indicated. If the fetal lie is unfavorable, the patient may be asked to walk briefly and return, or the scan may be rescheduled for later the same day or the following morning — this is the most common reason for a two-day stay rather than a one-day visit.
• Step 9 — Real-Time Interpretation and Preliminary Findings: At most GAF Healthcare partner centers, the fetal cardiologist provides a preliminary verbal summary of findings immediately after the scan. Abnormal findings are explained sensitively, with genetic counseling support made available on the same day if required.
**PHASE 4: REPORTING, COUNSELING, AND NEXT STEPS (Day 2–3)**
• Step 10 — Formal Report Preparation: A comprehensive written fetal echocardiography report (typically 3–8 pages) is prepared, including still images and clips of all cardiac views, segmental diagnosis, Doppler measurements, and clinical interpretation. At most centers this is available within 12–24 hours of the scan.
• Step 11 — Post-Scan Consultation (Detailed Counseling Session): The fetal cardiologist meets with the patient and partner/family to review the full report. If a CHD is identified, the cardiologist explains the specific anatomy, anticipated hemodynamic significance, natural history, postnatal management options (medical, catheter-based, or surgical), prognosis for the index diagnosis, and the likely multidisciplinary team (MDT) involvement (pediatric cardiac surgery, neonatology, genetics). A pediatric cardiac surgeon may join this meeting if surgical planning is immediately relevant. All information is provided in writing and, where needed, via a translator arranged by GAF Healthcare.
• Step 12 — MDT Input and Second Opinion (Optional, Same Visit): GAF Healthcare can arrange an MDT case review — including pediatric cardiac surgeon, pediatric cardiologist, neonatologist, and fetal medicine specialist — during the same visit for complex diagnoses, so the family leaves with a clear, unified management plan rather than fragmented opinions.
• Step 13 — Telemedicine Follow-Up: A telemedicine consultation 1–2 weeks after return home is included in the GAF Healthcare package, allowing the fetal cardiologist to review the ongoing plan, answer questions that arise after the initial emotional impact of the diagnosis has settled, and coordinate with the patient's home obstetrician.
**PHASE 5: DEPARTURE AND POST-VISIT CARE**
• Step 14 — Fit-to-Fly Assessment: The attending fetal cardiologist and, if applicable, the obstetrician on call confirm maternal fitness for air travel before departure. For uncomplicated diagnostic scans with normal findings, return travel is possible on the same day or the following morning. For patients who have received emotionally complex diagnoses or who have a co-existing obstetric concern identified during the visit, a 24–48-hour observation period may be recommended before flying.
• Step 15 — Digital Records Transfer: All scan images, STIC volume datasets, and reports are provided on encrypted digital media and/or uploaded to a secure cloud platform for the patient's home cardiologist and obstetrician, ensuring seamless continuity of care.
• Step 16 — Long-Term Care Coordination: For patients whose fetal echo confirms a CHD requiring postnatal intervention, GAF Healthcare proactively initiates communication between the Indian or UAE fetal cardiology team and neonatal/pediatric cardiac surgical units at the destination of delivery, facilitating coordinated peripartum planning across international borders.
Risks & Considerations
Fetal echocardiography using diagnostic ultrasound is considered one of the safest imaging modalities available in medicine: there is no ionizing radiation, and extensive evidence accumulated over more than four decades establishes no demonstrable harm to mother or fetus at the acoustic output levels used in diagnostic scanning. However, patients should be informed of the following clinically relevant considerations:
**Diagnostic limitations and false-negative findings**: No echocardiographic technique achieves 100% sensitivity for all cardiac lesions. Small ventricular septal defects (<2 mm), mildly abnormal valves, and subtle outflow tract discordance may be missed even at expert centers. A normal fetal echo reduces but does not eliminate the risk of CHD; the reported false-negative rate for major CHD at experienced centres is approximately 5–15%, depending on the specific lesion type, gestational age, maternal habitus, and fetal lie. Patients must understand that a normal result does not guarantee a structurally normal heart at birth.
Top Hospitals for Fetal Echocardiography
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Kings College Hospital Dubai
Dubai, UAE
Aster Hospital Dubai
Dubai, UAE
Top Doctors for Fetal Echocardiography
Internationally trained specialists in Gynecology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Geetanjli Behl
Fellowship in Fetal Medicine, DNB (Diplomate of National Board) — Obstetrics & Gynecology, DGO (Diploma in Gynaecology & Obstetrics), MBBS
Obstetrician, Gynecologist & Fetal Medicine Specialist
Medanta - The Medicity, Gurugram, India
22+ Yearsof experience
Dr. Geetanjli Behl is a Senior Consultant in Obstetrics, Gynecology, and Fetal Medicine at Medanta — The Medicity, one of India's most respected multi-specialty hospitals. With more than 22 years of hands-on clinical experience, she has built a reputation for caring for women through every stage of life — from managing complex pregnancies to treating challenging gynecological conditions with skill and empathy. Her training spans some of India's finest… Read more
Dr. Reshma Krishnan
MBBS, DGO (Diploma in Gynecology and Obstetrics), PGDHA (Post Graduate Diploma in Hospital Administration), Advanced Certification in Fetal Medicine & Gynae USG
Gynecologist & Fetal Medicine Specialist
Medicover Hospital, Bangalore, Bengaluru, India
27+ Yearsof experience
Dr. Reshma Krishnan is a highly regarded Consultant in Fetal Medicine, Sonology, Obstetrics, and Gynecology based in Bengaluru, with over 27 years of experience caring for women at every stage of their reproductive lives. She currently practices at Medicover Hospital, Bangalore, bringing a wealth of clinical depth and a calm, reassuring presence that patients and families often describe as genuinely comforting. Her advanced certification in fetal medicine… Read more
Dr. Tarang Preet Kaur
MBBS, MS, MRCOG, MCh, Fellowship in Urogynaecology, Fellowship in Cosmetic Gynaecology
Urogynaecologist
Max Super Speciality Hospital, Saket, New Delhi, India
11+ Yearsof experience
Dr. Tarang Preet Kaur is a Consultant in Urogynaecology with over 11 years of clinical experience, currently practicing at Max Super Speciality Hospital, Saket in New Delhi. She holds an MCh in Urogynaecology from Edge Hill University, United Kingdom (2024), the MRCOG from the Royal College of Obstetricians & Gynaecologists, and an MS in Obstetrics & Gynaecology from Maulana Azad Medical College, Delhi. Her dual qualification across India and the UK… Read more
Dr. Amrinder Kaur Bajaj
MBBS, MD — Obstetrics & Gynaecology (Gold Medalist), Senior Residency — Obstetrics & Gynaecology, FRSH — Fellow of the Royal Society of Health, FIAMS — Fellow of the Indian Association of Medical Specialists
Obstetrician & Gynaecologist
Fortis Hospital, Gurgaon, Gurgaon, India
42+ Yearsof experience
Dr. Amrinder Kaur Bajaj is one of Delhi-NCR's most experienced gynaecologists, with over four decades spent caring for women at every stage of life. She currently practises as a Consultant in Obstetrics & Gynaecology at Fortis Hospital, Gurgaon, where she brings together deep clinical knowledge and a quietly reassuring bedside manner that patients — and their families — find genuinely comforting. Her academic journey set a high bar early on. She completed… Read more
Dr. Anuradha Khurana
MBBS, DGO (Diploma in Obstetrics & Gynaecology), PG in High Risk Pregnancy and Infertility
Gynecologist & Obstetrics Specialist
Artemis Hospital, New Delhi, India
20+ Yearsof experience
Dr. Anuradha Khurana is a Senior Consultant in Obstetrics and Gynecology at Artemis Hospital, Delhi, with over two decades of hands-on experience in women's health. She is particularly well regarded for her work in high-risk pregnancy management, uterine conditions like fibroids and endometriosis, and complex gynecological surgeries. Patients and families consistently describe her as someone who takes the time to truly listen — and to explain things in a… Read more
Frequently Asked Questions — Fetal Echocardiography
The cost of a comprehensive fetal echocardiography — including the full segmental 2D/M-mode examination, color flow Doppler, pulsed and continuous-wave spectral Doppler, and 4D spatio-temporal image correlation (STIC) where clinically indicated — ranges from approximately USD $150 to $500 at JCI- and NABH-accredited centers in India (including cities such as Mumbai, Delhi, Chennai, Bangalore, and Hyderabad). In the UAE, specifically at JCI-accredited and DHA-licensed facilities in Dubai and Abu Dhabi, the equivalent comprehensive examination costs between approximately USD $400 and $1,200. This means India is typically 60–75% less expensive than the UAE for the same diagnostic procedure, while both destinations remain substantially more affordable than the United Kingdom (GBP £800–£1,500), the United States (USD $1,500–$3,500), or Australia (AUD $800–$2,000) for a comparable specialist fetal echocardiography service. It is important to note that these are estimates for the diagnostic scan only; if the findings necessitate an immediate follow-up MDT consultation, genetic counseling, or onward referral for fetal cardiac intervention, additional costs will apply and GAF Healthcare will provide a detailed itemized quote in advance. All GAF Healthcare cost packages are presented transparently, with no hidden fees, and include the coordinator fee, report preparation, and one post-visit telemedicine follow-up consultation.
Because fetal echocardiography is a non-invasive, non-sedating diagnostic ultrasound procedure with no physical intervention on the mother's body, the medical recovery time is zero — there is no surgical wound, no anesthesia, and no physiological disruption to the pregnancy from the scan itself. For most patients, the procedure and immediate post-scan consultation are completed within a single day, and return air travel is medically safe from the following morning. GAF Healthcare recommends a minimum stay of 2 days (Day 1: scan and preliminary consultation; Day 2: formal report review, counseling session, and any additional MDT input or follow-up imaging), allowing patients to receive their complete written report, have all questions answered, and travel home with a clear management plan rather than waiting for remote report delivery. Patients with complex diagnoses requiring MDT review may benefit from a 3–4 day stay. The primary travel-limiting considerations are not procedure-related but pregnancy-related: standard international aviation and obstetric guidelines recommend that pregnant women at or beyond 28 weeks carry a physician's letter confirming gestational age and fitness to fly; most airlines restrict travel beyond 36 weeks for singleton pregnancies. Patients with pre-existing obstetric risk factors (multiple pregnancy, cervical incompetence, placenta praevia, prior preterm labor) should obtain explicit clearance from both their home obstetrician and the treating fetal cardiologist at the GAF Healthcare partner center before planning their return flight. Compression stockings and adequate in-flight hydration are recommended for all pregnant travelers on flights exceeding 4 hours.
Fetal echocardiography at experienced, high-volume tertiary centers — such as those in the GAF Healthcare network in India and the UAE — achieves a diagnostic sensitivity of 85–92% for all structural congenital heart defects (CHDs) combined, and up to 95–99% for critical CHDs (those requiring surgical or catheter intervention within the first year of life) such as hypoplastic left heart syndrome, transposition of the great arteries, tetralogy of Fallot, and total anomalous pulmonary venous connection. This contrasts with a routine four-chamber view on the standard anatomy scan, which detects only approximately 40–60% of significant CHDs. The false-negative rate (a structurally abnormal heart that appears normal on fetal echo) is approximately 5–15%, depending on lesion type, technical factors, and gestational age — this is an internationally reported limitation of the technology rather than a reflection of individual center performance. A 'successful outcome' in the context of fetal echocardiography means: (1) a normal result accurately predicts the absence of significant CHD in over 99% of cases (very high negative predictive value); (2) where a CHD is confirmed, the prenatal diagnosis enables delivery planning at a cardiac center with immediate access to prostaglandin E1 infusion, neonatal intensive care, and surgical teams — meta-analyses and large registry studies consistently demonstrate that prenatal diagnosis of critical CHD reduces preoperative mortality by 30–50% and improves first-year survival by 15–25% compared to postnatal diagnosis. For fetal arrhythmias diagnosed echocardiographically, pharmacological in-utero treatment achieves conversion to sinus rhythm in approximately 80–90% of cases of SVT and atrial flutter. The goal of the procedure is not to treat the heart defect in utero (except in the rare scenarios of fetal cardiac intervention), but to provide the highest-quality diagnostic information possible, enabling a care team to give the baby the best possible start at birth.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides a fully integrated medical tourism support infrastructure that extends well beyond the clinical appointment itself, ensuring that international patients traveling to India or the UAE for fetal echocardiography experience a seamless, low-stress journey at what is often an emotionally sensitive time in pregnancy.
**INDIA — VISA AND ENTRY SUPPORT** India's e-Medical Visa (eMV) is available to citizens of 156+ countries and can be applied for entirely online through the Indian government's visa portal (indianvisaonline.gov.in). GAF Healthcare's documentation team prepares and reviews the complete visa application package: the hospital appointment letter on official letterhead, a letter of invitation from the treating fetal cardiologist, guidance on financial documentation, and step-by-step form-filling assistance. The e-Medical Visa is typically approved within 3–5 business days and permits up to 3 entries within 60 days, which accommodates patients who may need to return for a follow-up scan or for further evaluation. An e-Medical Attendant Visa is simultaneously arranged for the patient's spouse, family member, or support person, permitting them to accompany the patient throughout.
**UAE — VISA AND ENTRY SUPPORT** The United Arab Emirates offers visa-free entry or visa-on-arrival to citizens of more than 90 countries, including the European Union, United Kingdom, United States, Canada, Australia, and most GCC nations, for periods ranging from 30 to 90 days. For patients from countries requiring advance visa arrangement, GAF Healthcare coordinates a UAE medical visitor visa or tourist visa through the facility's international patient department. The entire UAE visa process is typically completed within 3–7 working days. GAF Healthcare provides the formal hospital invitation letter required as supporting documentation for the visa application.
**AIRPORT TRANSFERS** GAF Healthcare arranges private, air-conditioned airport-to-hospital-to-accommodation transfers for all patients and their attendants. Vehicles are pregnancy-appropriate (smooth suspension, adequate seating space, wheelchair accessibility if required) and driven by vetted chauffeurs familiar with hospital routes. Transfer times from major airports to GAF Healthcare partner hospitals are: Mumbai (BOM) or Delhi (DEL) to hospital — 30–60 minutes depending on traffic; Chennai (MAA) — 30–45 minutes; Dubai International (DXB) to hospital — 15–40 minutes; Abu Dhabi International (AUH) — 20–35 minutes.
**DEDICATED PATIENT COORDINATORS AND TRANSLATION SERVICES** Each patient is assigned a dedicated GAF Healthcare patient coordinator who serves as a single point of contact from pre-travel preparation through post-visit follow-up. The coordinator accompanies the patient in person to all hospital appointments, provides real-time interpretation during clinical consultations where needed (languages supported include Arabic, Russian, Swahili, French, Bengali, Urdu, Tagalog, and others on request), and manages all administrative interactions including appointment scheduling, bill settlement, and report collection. Professional medical interpreters — rather than family members or non-clinical staff — are used for all clinical discussions involving diagnosis communication, in compliance with the patient's right to accurate medical information.
**ACCOMMODATION FOR PATIENT AND ATTENDANT** GAF Healthcare has negotiated preferred rates at hospital-adjacent hotels and serviced apartments (ranging from comfortable 3-star to premium 5-star options depending on patient preference and budget) within 5–15 minutes of all partner hospitals. Accommodations are selected for pregnancy-friendly features: elevator access, proximity to 24-hour pharmacies, clean and hygienic food options, and proximity to obstetric emergency care if needed. For patients who require extended stays (e.g., for MDT consultation, follow-up scanning, or travel clearance), GAF Healthcare manages accommodation extension with zero penalty booking terms.
**TELEMEDICINE FOLLOW-UP AND ONGOING COORDINATION** All fetal echocardiography packages coordinated by GAF Healthcare include a minimum of one post-return telemedicine consultation with the treating fetal cardiologist, typically scheduled 10–14 days after the patient returns home. Scan datasets and reports are available on GAF Healthcare's secure digital platform and can be shared with the patient's home medical team with one-click authorization. For patients with confirmed CHD who require ongoing international multidisciplinary coordination — between fetal cardiologists in India or UAE, obstetricians at home, and neonatal cardiac surgeons — GAF Healthcare's clinical team actively manages this communication pathway throughout the remainder of the pregnancy.